Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

• Status: Completed
• Trial end date: 2019-11-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the use of subcutaneous (injected under the skin) immunoglobulin replacement therapy (replacement of antibodies, which are infection-fighting proteins) in patients with a type of blood cancer called lymphoma, who have been treated with rituximab (a type of chemotherapy) and have an abnormal immune system putting them at increased risk of infection.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rochester General Hospital
• Treatments: Antibodies; Immunoglobulins; Immunoglobulins, Intravenous; Rituximab

Criteria

Inclusion Criteria:

1. Diagnosis of B cell non-Hodgkin's lymphoma

2. Medically stable

3. Able to understand and willingness to sign a written informed consent

4. Able to comply with study procedures

Exclusion Criteria:

1. Previously diagnosed primary immunodeficiency

2. Additional immunosuppressive states

3. Ongoing therapy with Ig replacement